arrow
A

Andrea Antinori

national institute for infectious diseases lazzaro spallanzani
H指数:87
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)

HIV-1病毒学抑制患者转换为每日一次口服多拉韦林联合拉替拉韦的疗效与安全性:一项随机、开放标签、多中心Ⅱ期研究(DORAL)

2026-10-070
PRE
Clinical outcomes, safety and predictors of disease progression in high-risk COVID-19 outpatients treated with nirmatrelvir/ritonavir: an Italian multicenter retrospective cohort study (PRIMA study)
2026-09-210
OAAI
Clinical management of pregnancy, delivery and breastfeeding in women living with HIV in Italy: A survey of participating infectious diseases centres

意大利HIV感染者妊娠期、分娩期及哺乳期临床管理:参与性传染病中心的调查

2026-09-150
PRE
Ion Torrent Genexus as a Fast and Reliable Solution for HIV-1 Drug Resistance Testing: Comparison with the GeneStudio S5 Workflow

Ion Torrent Genexus作为HIV-1药物耐药性检测的快速可靠解决方案:与GeneStudio S5工作流的比较

2026-07-230
OA
Rapid achievement of protective cabotegravir concentrations in a real-world HIV PrEP cohort

在真实世界HIV PrEP队列中快速达到保护性卡博特格韦浓度

2026-07-010
OAAI
TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses

TTV病毒血症及针对猴痘病毒和登革病毒的疫苗接种后免疫应答

2026-05-190
OAAI
Successful use of isavuconazole as secondary prophylaxis of cryptococcal meningitis in a person living with HIV and AIDS: a case report

伊曲康唑作为隐球菌脑膜炎的二级预防在一名HIV和艾滋病感染者中的成功应用:病例报告

2026-03-200
OA
Improved HIV-1 Subtyping Accuracy Using near Full-Length Sequencing: A Comparison of Common Tools

使用近全长测序提高HIV-1分型准确性:常用工具的比较

2025-12-020
OAAI
Mental Health, Stigma and Risk Perception Among Early Adopters of HIV PrEP with LA Cabotegravir in Italy: A Multicenter Cross-Sectional and Implementation Study

心理健康、污名及风险认知:意大利使用长效卡博特格韦的HIV PrEP早期采纳者多中心横断面与实施研究

2025-12-010
OAAI
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial

整合酶抑制剂与蛋白酶抑制剂疗法在晚期HIV疾病中的比较(LAPTOP):一项多国家、随机、开放标签、非劣效性试验

2025-12-010
OAAI
Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies

生活质量及治疗满意度:接受Bictegravir/Emtricitabine/Tenofovir Alafenamide转换治疗的HIV感染者——基于观察性队列研究的合并分析

2025-11-240
OAAI
Inflammatory Milieu and Specific T-Cell Response Observed Three Months and One Year After SARS-CoV-2 Infection in Long COVID Subjects

长期新冠患者感染SARS-CoV-2后三个月和一年观察到的炎症微环境及特异T细胞应答

2025-10-270
OAAI
Long-term trajectories of Hepatic and Metabolic biomarkers after switching from TDF to TAF in ART-Experienced PWH with and without Hepatic Coinfection: Data from the ICONA Cohort

从TDF转换为TAF后,在伴有和不伴有肝共感染的经治人类免疫缺陷病毒感染者中,肝脏和代谢生物标志物的长期变化轨迹:ICONA队列研究数据

2025-10-040
OAAI
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments

SARS-CoV-2感染后,活动性血液疾病患者在接受联合抗病毒治疗情况下重新开始抗癌治疗的时间

2025-10-010
OAAI
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort

HIV感染者中一线拉米夫定/多替拉韦抗逆转录病毒疗法的有效性:ICONA基金会队列的真实世界数据

2025-09-010
PRE